Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sunitinib in pediatric and young adult recurrent or progressive brain tumors
2018-004520-10Phase 2
- Sponsor
- National Cancer Institute
- Start
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of sunitinib in high-grade glioma (HGG) and ependymoma (2 arms), sponsored by National Cancer Institute. Primary endpoint: Objective Response Rate at 8 weeks.
02
Drugs
sunitinib
03
Conditions
high-grade glioma (HGG)ependymoma
Beyond the preview
Go deeper on 2018-004520-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004520-10.